Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $20.88

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $20.8750.

Several research firms have weighed in on HCM. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a research report on Wednesday, October 8th. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Zacks Research cut shares of HUTCHMED from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 9th. Finally, Morgan Stanley lowered HUTCHMED from an “equal weight” rating to an “underweight” rating and dropped their target price for the stock from $18.00 to $13.75 in a report on Monday, September 22nd.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. boosted its stake in shares of HUTCHMED by 4.7% in the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after buying an additional 698 shares during the period. M&G PLC grew its holdings in shares of HUTCHMED by 0.4% during the second quarter. M&G PLC now owns 259,617 shares of the company’s stock worth $3,894,000 after purchasing an additional 924 shares during the last quarter. Bank of America Corp DE raised its stake in shares of HUTCHMED by 5.9% during the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock valued at $343,000 after acquiring an additional 1,209 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of HUTCHMED by 12.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after buying an additional 1,873 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of HUTCHMED by 19.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after purchasing an additional 4,116 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

HUTCHMED Stock Performance

NASDAQ HCM opened at $14.22 on Friday. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $15.45 and a 200-day moving average of $15.64. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $19.50.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.